Anadis offered Commercial Ready Grant for ‘Decoy Profiling Technology’ Anadis Limited (ASX:ANX) is proud to announce success in being offered a $973,000 Australian Government Commercial Ready Grant, to develop the Technology Strategy: ‘Decoy Profiling Technology’ or DPT.
DPT enables the removal of ‘decoy’ materials from vaccines, leading to greatly increased levels of specific beneficial antibody production. It is believed DPT will be able to improve vaccine technology to the extent which allows cost effective antibody production for the multi billion dollar Functional and Medical Food markets.
Federal Industry Minister Ian Macfarlane today congratulated Anadis Limited on being offered the Australian Government Commercial Ready grant for its decoy profiling technology project.
"Australia has a strong record in medical research fields, and through our Commercial Ready program, the Australian Government is pleased to support innovative companies, like Anadis commercialise world-class research and development," Mr Macfarlane said.
Functional and Medical Foods Functional and Medical Foods deliver a benefit to health and well-being over and above their usual nutritional value. Advances in bio-technology and nutritional sciences are increasingly shedding light on the “you are what you eat” principle, and it is no surprise that this is one of the fastest growing food segments in many developed countries.
This global market is forecast to grow to US$167 billion by 2010, over 15% annually. Key consumer trends in the functional food market include: growing attention to health, high motivation to take control of personal health, an ageing population and cost increases in health care.
Anadis Commercial Advantages Currently Anadis is able to provide commercial quantities of specific colostrum derived antibodies for OTC (over the counter) pharmaceutical and nutraceutical products.
Although antibodies have the potential to be used effectively in many applications in the functional food area, current antibody production costs prohibit their use in this large and growing market.
Utilising our existing antibody development stable – in particular EV-71 (Enterovirus 71 antibodies) - Anadis aims to produce antibodies for functional foods in as soon as 18 months.
Key Commercial Opportunities Anadis sees potential for the DPT technology strategy to improve specific antibody yields in colostrum, and therefore reduce antibody costs across our pipeline of products.
This cost reduction will allow Anadis to provide new products for ‘Population Health’, in addition to our current product pipeline for ‘Individual Recovery and Protection’.
It has been identified that if Enterovirus 71 antibodies can be integrated into functional foods, this would provide an additional market significantly larger than that identified for the Anadis OTC EV-71 preventative, for which current conservative estimates stand around 110 million doses per annum for Taiwan alone.
Intellectual Property Decoy Profiling Technology is covered by an Anadis patent application and by two other provisional patents in preparation. If successful, DPT has the scope for use in other active vaccines (human and animal), with out-licensing opportunities.
Research Details Decoy Profiling Technology builds on well established Anadis research programs. The DPT project is to be funded for 3 years, beginning February 2006 and ending January 2009. Initially this work will focus on the existing stable of vaccines, for use in cattle, developed by Anadis for antibody production in the areas of Enterovirus 71, E. coli and Helicobacter pylori (H.pylori).
Pezz
ANX Price at posting:
0.0¢ Sentiment: None Disclosure: Held
